You are here: Home: CCU 5 | 2005: Axel Grothey, MD: Select publications
Select publications
Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract
Arkenau H et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Presentation. ASCO 2005;Abstract 3507.
De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Presentation. ASCO 2005;Abstract 3501.
Hickish T et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. Presentation. ASCO 2004;Abstract 3619.
Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Presentation. ASCO 2005;Abstract 3515.
Lenz HJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Presentation. ASCO 2004;Abstract 3510.
Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presentation. ASCO 2005;Abstract 3508.
Sargent DJ et al. Disease-free survival (DFS) vs overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Presentation. ASCO 2004;Abstract 3502.
Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005a;352(26):2696-704. Abstract
Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Presentation. ASCO 2005b;Abstract 3521.
Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Presentation. ASCO 2005;Abstract LBA3500.
|
